Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier
This article was originally published in The Pink Sheet
Executive Summary
Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.